380 related articles for article (PubMed ID: 17383573)
1. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
[TBL] [Abstract][Full Text] [Related]
2. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
[TBL] [Abstract][Full Text] [Related]
3. Deuterated
Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.
Kilbourn MR; Hockley B; Lee L; Hou C; Goswami R; Ponde DE; Kung MP; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):233-7. PubMed ID: 17383572
[TBL] [Abstract][Full Text] [Related]
5. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus.
Kung MP; Hou C; Lieberman BP; Oya S; Ponde DE; Blankemeyer E; Skovronsky D; Kilbourn MR; Kung HF
J Nucl Med; 2008 Jul; 49(7):1171-6. PubMed ID: 18552132
[TBL] [Abstract][Full Text] [Related]
6. Effects of anesthetics on vesicular monoamine transporter type 2 binding to ¹⁸F-FP-(+)-DTBZ: a biodistribution study in rat brain.
Chen Z; Tang J; Liu C; Li X; Huang H; Xu X; Yu H
Nucl Med Biol; 2016 Jan; 43(1):124-129. PubMed ID: 26526872
[TBL] [Abstract][Full Text] [Related]
7. An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [
Zhao C; Liu C; Tang J; Xu Y; Xie M; Chen Z
Mol Imaging Biol; 2020 Apr; 22(2):265-273. PubMed ID: 31165386
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of
Naganawa M; Lin SF; Lim K; Labaree D; Ropchan J; Harris P; Huang Y; Ichise M; Carson RE; Cline GW
Nucl Med Biol; 2016 Dec; 43(12):743-751. PubMed ID: 27673755
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [
Naganawa M; Lim K; Nabulsi NB; Lin SF; Labaree D; Ropchan J; Herold KC; Huang Y; Harris P; Ichise M; Cline GW; Carson RE
Mol Imaging Biol; 2018 Oct; 20(5):835-845. PubMed ID: 29468404
[TBL] [Abstract][Full Text] [Related]
10. PET imaging with [
Tang J; Xu Y; Liu C; Fang Y; Cao S; Zhao C; Huang H; Zou M; Chen Z
Nucl Med Biol; 2020; 90-91():1-9. PubMed ID: 32861175
[TBL] [Abstract][Full Text] [Related]
11. PET Imaging of Vesicular Monoamine Transporter 2 in Early Diabetic Retinopathy Using [
Li J; Chen P; Bao Y; Sun Y; He J; Liu X
Mol Imaging Biol; 2020 Oct; 22(5):1161-1169. PubMed ID: 31650482
[TBL] [Abstract][Full Text] [Related]
12. VMAT2 imaging agent, D6-[
Zhao R; Zha Z; Yao X; Ploessl K; Choi SR; Liu F; Zhu L; Kung HF
Nucl Med Biol; 2019; 72-73():26-35. PubMed ID: 31330409
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
[TBL] [Abstract][Full Text] [Related]
14. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine.
Kung HF; Lieberman BP; Zhuang ZP; Oya S; Kung MP; Choi SR; Poessl K; Blankemeyer E; Hou C; Skovronsky D; Kilbourn M
Nucl Med Biol; 2008 Nov; 35(8):825-37. PubMed ID: 19026944
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) in a MPTP-lesioned PD mouse model.
Chao KT; Tsao HH; Weng YH; Hsiao IT; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lin KJ
Synapse; 2012 Sep; 66(9):823-31. PubMed ID: 22623146
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands.
Zheng P; Lieberman BP; Choi SR; Plöessl K; Kung HF
Bioorg Med Chem Lett; 2011 Jun; 21(11):3435-8. PubMed ID: 21531556
[TBL] [Abstract][Full Text] [Related]
17. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET.
Lin KJ; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Hsiao IT
PLoS One; 2013; 8(9):e75952. PubMed ID: 24098749
[TBL] [Abstract][Full Text] [Related]
18. MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons.
Xu Y; Tang J; Liu C; Zhao C; Cao S; Yu H; Chen Z; Xie M
Nucl Med Biol; 2021; 96-97():9-18. PubMed ID: 33647803
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 10-(11) C-dihydrotetrabenazine as a vesicular monoamine transporter 2 radioligand.
Li X; Chen Z; Tang J; Liu C; Zou P; Huang H; Tan C; Yu H
Arch Pharm (Weinheim); 2014 May; 347(5):313-9. PubMed ID: 24497196
[TBL] [Abstract][Full Text] [Related]
20. PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [¹⁸F]FP-DTBZ in baboons.
Harris PE; Farwell MD; Ichise M
Nucl Med Biol; 2013 Jan; 40(1):60-4. PubMed ID: 23102539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
